The International Myeloma Foundation says newly published data confirm REVLIMID plus low-dose dexamethasone improves survival and other measures of efficacy, compared to MPT , a standard of care for newly diagnosed multiple myeloma patients who are not eligible for a stem cell transplant. The study also demonstrates that continuing use of REVLIMID-dexamethasone instead of stopping after a fixed number of treatments provides further advantages in multiple measures including overall survival, progression-free survival, time to disease progression, overall response rate, and duration of response.
http://ift.tt/1rwk9fo
http://ift.tt/1rwk9fo
No comments:
Post a Comment